Study of Dasatinib in Patients with CML

Article

This clinical trial will assess the safety of dasatinib and whether this drug can help control CML in chronic phase. The study is split into two arms, with patients starting on a dosage of either 100 mg once daily or 50 mg twice daily of dasatinib.

Study Type: Interventional

Age/Sex Requirements: 16 years+ (None)

Sponsor: MD Anderson Cancer Center

Purpose: This clinical trial will assess the safety of dasatinib and whether this drug can help control CML in chronic phase. The study is split into two arms, with patients starting on a dosage of either 100 mg once daily or 50 mg twice daily of dasatinib. The primary outcome measure will be the time to first molecular response prior to 12 months.

Click here to access this third-party website.

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
Video 10 - "Future Treatment Landscape for COPD"
Video 9 - "Emerging Treatment Approaches in COPD"
A panel of 4 experts on HIV
A panel of 4 experts on HIV
Kelly Nichols, OD; Laura Periman, MD; and Mile Brujic, OD
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
© 2024 MJH Life Sciences

All rights reserved.